Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Promising data could point to new factor H therapy option
March 2017
SHARING OPTIONS:

FREIBURG, Germany—A team of researchers from Greenovation Biotech GmbH, the University of Freiburg and the University of Jena have been able to show full bioactivity of the human complement factor H produced in the Physcomitrella patens moss. It was shown to be able to control complement activation in serum derived from aHUS patients and in a C3G mouse model. Genetic defects in complement regulatory proteins can result in diseases such as atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathies (C3G) and age-related macular degeneration. Most mutations affect the glycoprotein complement factor H, and while replacement therapy with recombinantly produced factor H is an option, the compound is not yet available for clinical use. The results were published in the Journal of the American Society of Nephrology in a paper titled “Moss-produced, glycosylation-optimized human factor H for therapeutic application in complement disorders.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.